Publications by Yugang Guo | EPFL Graph Search

Related publications (12)

IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases

Li Tang, Yi Wang, Yugang Guo, Bing Feng, Yang Zhao, Yuqing Xie, Xiaomeng Hu, Min Gao

The success of chimeric antigen receptor (CAR) T cell therapy in treating several hematopoietic malignancies has been difficult to replicate in solid tumors, in part because of T cell exhaustion and eventually dysfunction. To counter T cell dysfunction in ...

Nature Portfolio2024

Switchable immune modulator for tumor-specific activation of anticancer immunity

Li Tang, Yugang Guo, Min Gao, Yu Zhao

Immune stimulatory antibodies and cytokines elicit potent antitumor immunity. However, the dose-limiting systemic toxicity greatly hinders their clinical applications. Here, we demonstrate a chemical approach, termed "switchable" immune modulator (Sw-IM), ...

2021

Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy

Georg Fantner, Li Tang, Mahmut Selman Sakar, Yugang Guo, Murat Kaynak, Mélanie Thérèse Marie Hannebelle, Armand Kurum, Kewen Lei, Lucia Bonati, Yuqing Xie, Min Gao, Veronika Cencen

Cancer cells enriched in cholesterol in their plasma membrane impair T-cell-mediated cytotoxicity, which can be augmented by stiffening the cancer cells via cholesterol depletion, as shown in mouse models of adoptive T-cell immunotherapy. Malignant transfo ...

2021

Engineering cancer vaccines using stimuli-responsive biomaterials

Li Tang, Yugang Guo, Yu Zhao

Cancer vaccines aimed at expanding the pool or increasing the activity of tumor-specific T cells against malignancies is an important immunotherapy modality that has been extensively pursued in the past decades. However, the clinical efficacy of cancer vac ...

2018

Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity

Li Tang, Yugang Guo, Bing Feng, Yang Zhao, Min Gao

Tang and colleagues show that a half-life-extended IL-10-Fc fusion protein acts directly on terminally exhausted PD1(+)TIM-3(+)CD8(+) T cells to enhance their proliferation and effector function by reprogramming the cellular metabolism to oxidative phospho ...

2021

Il-10 expressing cells for enhanced cancer immunotherapies

Li Tang, Yugang Guo, Yang Zhao

The present invention relates generally to the field of anti-cancer therapy, in particular to the use of adoptive T cell transfer therapy for treating cancer, in particular sold tumors. More specifically, the present invention relates to immune cells compr ...

2023

A Manganese Phosphate Nanocluster Activates the cGAS‐STING Pathway for Enhanced Cancer Immunotherapy

Li Tang, Yugang Guo, Armand Kurum, Kewen Lei, Yuqing Xie, Min Gao, Yu Zhao, Xiaomeng Hu

Targeting the stimulator of interferon genes (STING) pathway with cyclic dinucleotides (CDNs), the natural STING agonists, is a promising immunotherapeutic strategy for cancer. However, the clinical application of natural CDNs as therapeutics is greatly hi ...

2021

Highly effective adoptive t cell therapy

Li Tang, Yugang Guo, Bing Feng

The present invention relates generally to the field of anti-cancer therapy and autoimmune therapy, in particular to the use of adoptive T cell transfer therapy. More specifically, the present invention relates to compositions, pharmaceutical compositions ...

2023

The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer

Li Tang, Yi Wang, Yugang Guo, Bing Feng, Yang Zhao, Lucia Bonati, Weilin Li, Mei-Wen Peng, Rongrong Li, Tom Enbar, Xiaolei Zhou, Xinyi Huang

Current cancer immunotherapy predominately focuses on eliciting type 1 immune responses fighting cancer; however, long-term complete remission remains uncommon1,2. A pivotal question arises as to whether type 2 immunity can be orchestrated alongside type 1 ...

2024

Il-21 fusion proteins useful as enhancers of anti-cancer immunotherapies

Li Tang, Yi Wang, Yugang Guo

The present invention relates generally to the field of anti-cancer therapy, in particular to the use of agents or co-agents useful in anti-cancer immunotherapy such as adoptive T-cell transfer (ACT) immunotherapy and immune check-point blockades. ...

2024

A Magnetic Nanovaccine Enhances Cancer Immunotherapy

Li Tang, Yugang Guo

2019

Il10/fc fusion proteins useful as enhancers of immunotherapies

Li Tang, Yugang Guo, Yuqing Xie

The present disclosure relates to new agents useful for anti-cancer therapy such as anti-cancer adoptive T-cell transfer (ACT) immunotherapy or immune check-point blockade therapy and related compositions, uses and methods thereof. ...

2021